Skip to Content
Merck

[Genetic basis of primary hypertriglyceridemia].

Nihon rinsho. Japanese journal of clinical medicine (2013-11-12)
Takanari Gotoda
ABSTRACT

Rare monogenic and severe hypertriglyceridemia usually results from genetic abnormalities that lead to severely reduced activity of lipoprotein lipase (LPL), a crucial player in the hydrolysis of triglyceride(TG)-rich lipoproteins. These include mutations in the genes for LPL, APOC2, GPIHBP1, LMF1 and APOA5. On the other hand, recent results from genome-wide association studies(GWAS) or resequencing studies have revealed that common polygenic and mild hypertriglyceridemia results from accumulation of both common as well as rare risk variants under the influence of classical environmental conditions. Interestingly, some primary hyperlipoproteinemiae appear to share a common genetic basis, providing a recent interesting and unique hypothesis. Genetic analysis also could provide novel candidates for therapeutic targets and fundamental basis of establishment of more rational genetic risk scoring for hypertriglyceridemia.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lipoprotein Lipase from Burkholderia sp., lyophilized powder, ≥50,000 units/mg solid
Sigma-Aldrich
Lipoprotein Lipase from Pseudomonas sp., lyophilized, powder, yellow-brown, ≥160 U/mg
Sigma-Aldrich
Lipoprotein Lipase from Pseudomonas sp., lyophilized, powder, ≥1200 U/mg
Sigma-Aldrich
Lipoprotein Lipase from bovine milk, ammonium sulfate suspension, ≥2,000 units/mg protein (BCA)